Innoventric, an Israeli startup specializing in transcatheter tricuspid regurgitation (TR) treatment, has secured $28.5 million in Series B funding led by RA Capital Management, bringing its total funding to $41 million since its inception in 2017. The newly raised capital will be used to advance clinical trials and expand regulatory approvals in the U.S. and Europe, following successful completion of a first-in-human clinical trial in Europe. Innoventric's innovative device employs a heterotopic, cross-caval approach to treat TR by anchoring a prosthetic valve to the vena cava rather than the heart, thus reducing risks of leakage and simplifying the implantation process. The company has already treated over 40 patients and received FDA clearance for an Early Feasibility Study in the U.S. Innoventric's technology aims to address the severe medical issue affecting millions, particularly those who may not qualify for traditional treatments. With a focus on data-driven innovation, Innoventric is positioned to significantly improve patient outcomes in the $10 billion annual transcatheter heart valve replacement market.